Page 87 - GALENIKA MEDICAL JOURNAL

patients without a history of diabetes mellitus, and empagliflozin in a dose of 10 mg, as well as dapagliflozin in a dose of
10 mg, have been implemented in patients without diabetes mellitus. New directions for the expansion of the use of SGLT2
inhibitors have pointed towards their applicability in acute heart failure (sotagliflozin) and type 1 diabetes (sotagliflozin).

Recently, clinical studies concerning the use of empagliflozin and dapagliflozin in acute coronary syndrome (ACS), appeared.
The aim of this paper was to highlight the possible benefit of including SGLT2 inhibitors in patients with ACS.

Keywords: sodium-glucose co-transporter 2 inhibitors, acute coronary syndrome, treatment

Literatura 16. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et
al; SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with
Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021 Jan
1. Institute of Medicine (US) Committee on Social Security Cardiovascular 14;384(2):117-28.
Disability Criteria. Cardiovascular Disability: Updating the Social 17. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et
Security Listings. Washington (DC): National Academies Press (US); al; EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart
2010. Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Oct
2. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al; 14;385(16):1451-61.
Executive Group on behalf of the Joint European Society of Cardiology 18. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D,
(ESC)/American College of Cardiology (ACC)/American Heart Association Hernandez AF, et al; DELIVER Trial Committees and Investigators.
(AHA)/World Heart Federation (WHF) Task Force for the Universal Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection
Definition of Myocardial Infarction. Fourth Universal Definition of Fraction. N Engl J Med. 2022 Sep 22;387(12):1089-98.
Myocardial Infarction (2018). J Am Coll Cardiol. 2018 Oct 30;72(18):2231-
64. 19. Shimizu W, Kubota Y, Hoshika Y, Mozawa K, Tara S, Tokita Y, et al;
3. Mechanic OJ, Gavin M, Grossman SA. Acute Myocardial Infarction. EMBODY trial investigators. Effects of empagliflozin versus placebo on
cardiac sympathetic activity in acute myocardial infarction patients with
2022 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol. 2020
Publishing; 2022 Jan–. Sep 25;19(1):148.
4. Saisho Y. SGLT2 Inhibitors: the Star in the Treatment of Type 2 20. von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner
Diabetes? Diseases. 2020 May 11;8(2):14. M, et al. Empagliflozin in acute myocardial infarction: the EMMY trial.
5. Begic E, Aziri A, Obradovic S, Begic Z. Diabetes: total risk - benefit Eur Heart J. 2022 Nov 1;43(41):4421-32.
of SGLT2 inhibitors and GLP1 agonists. ESC, e-journal of cardiology 21. Udell JA, Jones WS, Petrie MC, Harrington J, Anker SD, Bhatt DL, et
practice. Available at: https://www.escardio.org/Journals/E-Journal- al. Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial
of-Cardiology-Practice/Volume-22/diabetes-total-risk-benefit-of-sglt2- Infarction: JACC Review Topic of the Week. J Am Coll Cardiol. 2022 May
inhibitors-and-glp1-agonists 24;79(20):2058-68.
6. Koufakis T, Mustafa OG, Tsimihodimos V, Ajjan RA, Kotsa K. Insights 22. Mozawa K, Kubota Y, Hoshika Y, Tara S, Tokita Y, Yodogawa K, et al.
Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Empagliflozin confers reno-protection in acute myocardial infarction
Inhibition the Cherry on the Cake of Cardiorenal Protection? Drugs. and type 2 diabetes mellitus. ESC Heart Fail. 2021 Oct;8(5):4161-73.
2021 Aug;81(12):1365-71.
23. Panchapakesan U, Pegg K, Gross S, Komala MG, Mudaliar H, Forbes J, et
7. Singh M, Kumar A. Risks Associated with SGLT2 Inhibitors: An Overview. al. Effects of SGLT2 inhibition in human kidney proximal tubular cells--
Curr Drug Saf. 2018;13(2):84-91. renoprotection in diabetic nephropathy? PLoS One. 2013;8(2):e54442.
8. Papadokostaki E, Rizos E, Tigas S, Liberopoulos EN. Canagliflozin and 24. Lahnwong S, Palee S, Apaijai N, Sriwichaiin S, Kerdphoo S, Jaiwongkam
Amputation Risk: Evidence So Far. Int J Low Extrem Wounds. 2020 T, et al. Acute dapagliflozin administration exerts cardioprotective
Mar;19(1):21-6. effects in rats with cardiac ischemia/reperfusion injury. Cardiovasc
9. Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetol. 2020 Jun 15;19(1):91.
Diabetologia. 2018 Oct;61(10):2079-86. 25. Sayour AA, Ruppert M, Oláh A, Benke K, Barta BA, Zsáry E, et al. Effects
10. Tye SC, de Vries ST, Wanner C, Denig P, Heerspink HJL. Prediction of the of SGLT2 Inhibitors beyond Glycemic Control-Focus on Myocardial
Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based SGLT1. Int J Mol Sci. 2021 Sep 12;22(18):9852.
on Short-Term Changes in Multiple Risk Markers. Front Pharmacol. 26. Michel MC, Mayoux E, Vallon V. A comprehensive review of the
2022 Jan 25;12:786706. pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and
11. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu humans. Naunyn Schmiedebergs Arch Pharmacol. 2015 Aug;388(8):801-
N, et al; CANVAS Program Collaborative Group. Canagliflozin and 16.
Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 27. von Lewinski D, Benedikt M, Tripolt N, Wallner M, Sourij H, Kolesnik E.
Aug 17;377(7):644-57. Can sodium-glucose cotransporter 2 inhibitors be beneficial in patients
12. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al; with acute myocardial infarction? Kardiol Pol. 2021;79(5):503-9.
DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular
Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-57.
13. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz Konflikt interesa: Nema
U, et al; VERTIS CV Investigators. Cardiovascular Outcomes with
Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020 Oct 8;383(15):1425- Primljeno: 10. 01. 2023.
35. Prihvaćeno: 02. 02. 2023.
14. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Onlajn: 01. 03. 2023.
Martinez FA, et al; DAPA-HF Trial Committees and Investigators.
Dapagliflozin in Patients with Heart Failure and Reduced Ejection
Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008.
15. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al;
EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal
Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 Oct
8;383(15):1413-24.

REVIJALNI RADOVI Galenika Medical Journal, 2023; 2(5):80-85. 85